These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 36991547)

  • 61. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study.
    Budde LE; Sehn LH; Matasar M; Schuster SJ; Assouline S; Giri P; Kuruvilla J; Canales M; Dietrich S; Fay K; Ku M; Nastoupil L; Cheah CY; Wei MC; Yin S; Li CC; Huang H; Kwan A; Penuel E; Bartlett NL
    Lancet Oncol; 2022 Aug; 23(8):1055-1065. PubMed ID: 35803286
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II Trial.
    Matasar M; Bartlett NL; Shadman M; Budde LE; Flinn I; Gregory GP; Kim WS; Hess G; El-Sharkawi D; Diefenbach CS; Huang H; To I; Parreira J; Wu M; Kwan A; Assouline S
    Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):240-253. PubMed ID: 38195322
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Elranatamab vs. teclistamab: battle of the BCMA bispecifics in relapsed/refractory multiple myeloma.
    Moore DC; Granger K; Hill H; Karabinos A; Davis JA
    Expert Rev Hematol; 2024 Jun; 17(6):197-200. PubMed ID: 38717927
    [No Abstract]   [Full Text] [Related]  

  • 64. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.
    Moreau P; Mateos MV; Berenson JR; Weisel K; Lazzaro A; Song K; Dimopoulos MA; Huang M; Zahlten-Kumeli A; Stewart AK
    Lancet Oncol; 2018 Jul; 19(7):953-964. PubMed ID: 29866475
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Incidence, clinical characteristics and prognosis of tumor lysis syndrome following B-cell maturation antigen-targeted chimeric antigen receptor-T cell therapy in relapsed/refractory multiple myeloma.
    Zhang Q; Zu C; Jing R; Feng Y; Zhang Y; Zhang M; Lv Y; Cui J; Zhou L; Meng Y; Wang L; Cen Z; Chang AH; Hu Y; Huang H
    Front Immunol; 2023; 14():1125357. PubMed ID: 37215107
    [TBL] [Abstract][Full Text] [Related]  

  • 66. CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myeloma.
    Firestone RS; McAvoy D; Shekarkhand T; Serrano E; Hamadeh I; Wang A; Zhu M; Qin WG; Patel D; Tan CR; Hultcrantz M; Mailankody S; Hassoun H; Shah US; Korde N; Maclachlan KH; Landau HJ; Scordo M; Shah GL; Lahoud OB; Giralt S; Murata K; Hosszu KK; Chung DJ; Lesokhin AM; Usmani SZ
    Blood Adv; 2024 Apr; 8(7):1600-1611. PubMed ID: 37878808
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Daily ascending dosing in cynomolgus monkeys to mitigate cytokine release syndrome induced by ERY22, surrogate for T-cell redirecting bispecific antibody ERY974 for cancer immunotherapy.
    Iwata Y; Sasaki M; Harada A; Taketo J; Hara T; Akai S; Ishiguro T; Narita A; Kaneko A; Mishima M
    Toxicol Appl Pharmacol; 2019 Sep; 379():114657. PubMed ID: 31326447
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Teclistamab as monotherapy in patients with relapsed or refractory multiple myeloma who received three or more lines of therapy].
    Le Grand S; Karlin L
    Bull Cancer; 2023 Sep; 110(9):871-872. PubMed ID: 37296008
    [No Abstract]   [Full Text] [Related]  

  • 69. FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome.
    Le RQ; Li L; Yuan W; Shord SS; Nie L; Habtemariam BA; Przepiorka D; Farrell AT; Pazdur R
    Oncologist; 2018 Aug; 23(8):943-947. PubMed ID: 29622697
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Talquetamab in multiple myeloma.
    Liu L; Krishnan A
    Haematologica; 2024 Mar; 109(3):718-724. PubMed ID: 37855056
    [TBL] [Abstract][Full Text] [Related]  

  • 71. T-Cell Characteristics Impact Response and Resistance to T-Cell-Redirecting Bispecific Antibodies in Multiple Myeloma.
    Verkleij CPM; O'Neill CA; Broekmans MEC; Frerichs KA; Bruins WSC; Duetz C; Kruyswijk S; Baglio SR; Skerget S; Montes de Oca R; Zweegman S; Verona RI; Mutis T; van de Donk NWCJ
    Clin Cancer Res; 2024 Jul; 30(14):3006-3022. PubMed ID: 38687588
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Tocilizumab for severe cytokine-release syndrome after haploidentical donor transplantation in a patient with refractory Epstein-Barr virus-positive diffuse large B-cell lymphoma.
    Ureshino H; Ando T; Kizuka H; Kusaba K; Sano H; Nishioka A; Itamura H; Shindo T; Kubota Y; Kojima K; Kimura S
    Hematol Oncol; 2018 Feb; 36(1):324-327. PubMed ID: 28971493
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Dawn of a new era of antibody-drug conjugates and bispecific T-cell engagers for treatment of multiple myeloma: a systematic review of literature.
    Khattak ZE; Hashmi H; Khan SI; Aamir S; Arif U; Khan AI; Darwin A; Singh AD; Khouri J; Anwer F
    Ann Hematol; 2021 Sep; 100(9):2155-2172. PubMed ID: 34318356
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study.
    Goebeler ME; Knop S; Viardot A; Kufer P; Topp MS; Einsele H; Noppeney R; Hess G; Kallert S; Mackensen A; Rupertus K; Kanz L; Libicher M; Nagorsen D; Zugmaier G; Klinger M; Wolf A; Dorsch B; Quednau BD; Schmidt M; Scheele J; Baeuerle PA; Leo E; Bargou RC
    J Clin Oncol; 2016 Apr; 34(10):1104-11. PubMed ID: 26884582
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Progressive Multifocal Leukoencephalopathy Unmasked by Teclistamab in a Refractory Multiple Myeloma Patient.
    Arvanitis P; Farmakiotis D; Pelcovits A
    Curr Oncol; 2024 May; 31(5):2670-2678. PubMed ID: 38785483
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Priming treatment with T-cell redirecting bispecific antibody ERY974 reduced cytokine induction without losing cytotoxic activity in vitro by changing the chromatin state in T cells.
    Iwata Y; Narushima Y; Harada A; Mishima M
    Toxicol Appl Pharmacol; 2022 Apr; 441():115986. PubMed ID: 35304238
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Teclistamab in Relapsed or Refractory Multiple Myeloma.
    Cliff ERS; Mian H; Mohyuddin GR
    N Engl J Med; 2022 Nov; 387(18):1721-1722. PubMed ID: 36322860
    [No Abstract]   [Full Text] [Related]  

  • 79. Teclistamab in Relapsed or Refractory Multiple Myeloma.
    Hindié E
    N Engl J Med; 2022 Nov; 387(18):1721. PubMed ID: 36322859
    [No Abstract]   [Full Text] [Related]  

  • 80. Teclistamab in Relapsed or Refractory Multiple Myeloma. Reply.
    Moreau P; Girgis S; Goldberg JD
    N Engl J Med; 2022 Nov; 387(18):1722-1723. PubMed ID: 36322861
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.